自引率: 7.5%
被引量: 19861
通过率: 暂无数据
审稿周期: 2
版面费用: 暂无数据
国人发稿量: 6
投稿须知/期刊简介:
Published by John Wiley and Sons. ISSN (printed): 0965-2140. ISSN (electronic): 1360-0443.<br />Addiction was established in 1884 and has been in continuous publication ever since the longest established journ Addiction is the official journal of the Society for the Study of Addiction, and has been in publication since 1884.<br style="color: #1c1d1e;" />The journal publishes peer-reviewed research reports on pharmalogical and behavioural addictions, bringing together research conducted within many different disciplines. Addiction's aims are: to provide an effective outlet for high quality research in the field of addiction by selecting excellent papers for publication and improving them through the review process, to stimulate debate with the field of addiction on matters relating to the science or its translation into clinical practice or policy to promote high quality research in the field of addiction worldwide through its publishing and other activities. Addiction's scope spans human experimental, epidemiological, social science, historical, clinical and policy research relating to addiction, primarily but not exclusively in the areas of psychoactive substance use and/or gambling. In addition to original research, the journal features editorials, commentaries, reviews, letters, and book reviews. Keywords substance abuse, addiction, addictive behaviour, alcohol abuse, drug abuse, tobacco control. tobacco abuse, addictive substances, alcohol dependence, drug use, nicotine dependence, smoking. Abstracting and Indexing Information Abstracts in Anthropology (Sage) Abstracts on Hygiene & Communicable Diseases (CABI) Academic Search (EBSCO Publishing) Academic Search Alumni Edition (EBSCO Publishing) Academic Search Elite (EBSCO Publishing) Academic Search Premier (EBSCO Publishing) AgeLine Database (EBSCO Publishing) Agricultural & Environmental Science Database (ProQuest) Biological Abstracts (Clarivate Analytics) Biological Science Database (ProQuest) BIOSIS Previews (Clarivate Analytics) British Nursing Database (ProQuest) CAB Abstracts® (CABI) CAS: Chemical Abstracts Service (ACS) CINAHL: Cumulative Index to Nursing & Allied Health Literature (EBSCO Publishing) Criminal Justice Abstracts (EBSCO Publishing) Criminal Justice Database (ProQuest) Criminology Collection (ProQuest) Current Contents: Clinical Medicine (Clarivate Analytics) Current Contents: Social & Behavioral Sciences (Clarivate Analytics) ERA: Educational Research Abstracts Online (T&F) Global Health (CABI) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) Health Source Nursing/Academic (EBSCO Publishing) HEED: Health Economic Evaluations Database (Wiley-Blackwell) Hospital Premium Collection (ProQuest) Ingenta Select Journal Citation Reports/Science Edition (Clarivate Analytics) Journal Citation Reports/Social Science Edition (Clarivate Analytics) Leisure Tourism Database (CABI) Leisure, Recreation & Tourism Abstracts (CABI) Medical Database (ProQuest) MEDLINE/PubMed (NLM) Natural Science Collection (ProQuest) Nursing & Allied Health Database (ProQuest) Nutrition Abstracts & Reviews Series A: Human & Experimental (CABI) Periodical Index Online (ProQuest) Postharvest News & Information (CABI) Proquest Business Collection (ProQuest) ProQuest Central (ProQuest) ProQuest Central K-19 ProQuest Politics Collection (ProQuest) ProQuest Sociology Collection (ProQuest) Psychology & Behavioral Sciences Collection (EBSCO Publishing) Psychology Collection (GALE Cengage) Psychology Database (ProQuest) PsycINFO/Psychological Abstracts (APA) PSYNDEX (ZPID) Public Health Database (ProQuest) PubMed Dietary Supplement Subset (NLM) Research Library (ProQuest) Research Library Prep (ProQuest) Review of Aromatic & Medicinal Plants (CABI) Rural Development Abstracts (CABI) Science Citation Index (Clarivate Analytics) Science Citation Index Expanded (Clarivate Analytics) SciTech Premium Collection (ProQuest) SCOPUS (Elsevier) Social Science Premium Collection (ProQuest) Social Sciences Citation Index (Clarivate Analytics) SocINDEX (EBSCO Publishing) Sociological Collection (EBSCO Publishing) Soils & Fertilizers Abstracts (CABI) Studies on Women & Gender Abstracts (T&F) Sugar Industry Abstracts (CABI) Tropical Diseases Bulletin (CABI) VINITI (All-Russian Institute of Science & Technological Information) Violence & Abuse Abstracts (EBSCO Publishing) World Agricultural Economics & Rural Sociology Abstracts (CABI)
期刊描述简介:
Addiction is a monthly peer-reviewed scientific journal established in 1884 by the Society for the Study of Addiction to Alcohol and other Drugs. It covers original research relating to alcohol, illicit drugs, tobacco, and behavioural addictions.
-
Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient- and prescriber-level characteristics in Massachusetts, USA.
Opioid use disorder (OUD) is treatable with buprenorphine/naloxone (buprenorphine), but many patients discontinue treatment prematurely. The aim of this study was to assess the influence of patient- and prescriber-level characteristics relative to several patient outcomes following the initiation of buprenorphine treatment for OUD. This was a retrospective observational investigation. We used the Public Health Data Warehouse from the Massachusetts Department of Public Health to construct a sample of patients who initiated buprenorphine treatment between 2015 and 2019. We attributed each patient to a prescriber based on information from prescription claims. We used multilevel models to assess the influence of patient- and prescriber-level characteristics on each outcome. Massachusetts, USA. The study cohort comprised 37 955 unique patients and 2146 prescribers. Among patients, 64.6% were male, 52.6% were under the age of 35 and 82.2% were White, non-Hispanic. For insurance coverage, 72.1% had Medicaid. The outcome measures were poor medication continuity, treatment discontinuation and opioid overdose, all assessed within a 12-month follow-up period that began with a focal prescription for buprenorphine. Each patient had a single follow-up period. Poor medication continuity was defined as medication gaps totaling more than 7 days during the initial 180 days of buprenorphine treatment and treatment discontinuation was defined as having a medication gap for 2 consecutive months within the 12-month follow-up period. The patient-level rates for poor medication continuity, treatment discontinuation and opioid overdose were 59.7% [95% confidence interval (CI) = 59.2-60.2], 57.4% (95% CI = 56.9-57.9) and 10.3% (95% CI = 10.0-10.6), respectively, with 1.1% (95% CI = 1.0-1.2) experiencing a fatal opioid overdose. At the patient level, after adjustment for covariates, adverse outcomes were associated with race/ethnicity as both Black, non-Hispanic and Hispanic patients had worse outcomes than did White, non-Hispanic patients (Black, non-Hispanic -- poor continuity: 1.50, 95% CI = 1.34-1.68; discontinuation: 1.44, 95% CI = 1.30-1.60; Hispanic -- poor continuity: 1.21, 95% CI = 1.12-1.31; discontinuation: 1.38, 95% CI = 1.28-1.48). Patients with insurance coverage through Medicaid also had worse outcomes than those with commercial insurance (poor continuity: 1.18, 95% CI = 1.11-1.26; discontinuation: 1.09, 95% CI = 1.03-1.16; overdose: 1.98, 95% CI = 1.75-2.23). Pre-treatment mental health conditions and other types of chronic illness were also associated with worse outcomes (History of mental health conditions -- poor continuity: 1.11, 95% CI = 1.06-1.17; discontinuation: 1.05, CI = 1.01-1.10; overdose: 1.47, 95% CI = 1.36-1.60; Chronic health conditions -- poor continuity: 1.15, 95% CI = 1.05-1.27; discontinuation: 1.15, 95% CI = 1.05-1.26; overdose: 1.83, 95% CI = 1.60-2.10; History of substance use disorder other than for opioids -- poor continuity: 1.54, 95% CI = 1.46-1.62; discontinuation: 1.54, 95% CI = 1.47-1.62; overdose: 1.93, 95% CI = 1.80-2.07). At the prescriber level, after adjustments for covariates, adverse outcomes were associated with clinical training, as primary care physicians had higher rates of adverse outcomes than psychiatrists (poor continuity: 1.12, 95% CI = 1.02-1.23; discontinuation: 1.04, 95% CI = 1.01-1.09). A larger prescriber panel size, based on number of patients being prescribed buprenorphine, was also associated with higher rates of adverse outcomes (poor continuity: 1.36, 95% CI = 1.27-1.46; discontinuation: 1.21, 95% CI = 1.14-1.28; overdose: 1.10, 95% CI = 1.01-1.19). Between 9% and 15% of the variation among patients for the outcomes was accounted for at the prescriber level. Patient- and prescriber-level characteristics appear to be associated with patient outcomes following buprenorphine treatment for opioid use disorder. In particular, patients' race/ethnicity and insurance coverage appear to be associated with substantial disparities in outcomes, and prescriber characteristics appear to be most closely associated with medication continuity during early treatment.
被引量：- 发表：1970
-
Effect of nicotine mouth spray on urges to vape: A randomized, placebo-controlled, pharmacodynamic clinical trial in exclusive e-cigarette users.
被引量：- 发表：1970
-
Early detection and prediction of non-fatal drug-related incidents and fatal overdose outbreaks using the Farrington algorithm.
被引量：- 发表：1970
-
Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions.
被引量：- 发表：1970
-
Managing the exponential growth of Mendelian randomization studies.
被引量：- 发表：1970
